Skip to main content

Advertisement

Table 3 Changes in outcome parameters after 24 weeks treatment

From: Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes

Variable The group A (n = 29) The group B (n = 27)
Baseline 24 weeks Baseline 24 weeks
Triglyceride (mmol/L) 3.26 ± 1.14 3.16 ± 1.12 3.28 ± 1.16 3.24 ± 1.15
Total Cholesterol (mmol/L) 6.23 ± 1.41 6.18 ± 1.72 6.19 ± 1.51 6.17 ± 1.68
HDL-Cholesterol (mmol/L) 1.04 ± 0.23 1.14 ± 0.38 1.12 ± 0.21 1.13 ± 0.24
LDL-Cholesterol (mmol/L) 4.13 ± 1.01 3.67 ± 1.12 4.20 ± 1.02 3.81 ± 1.20
Serum C peptide (ng/ml) 1.06 ± 0.68 1.18 ± 0.66 1.06 ± 0.70 1.10 ± 0.69
HMW adiponectin (ug/ml) 3.12 ± 1.56 5.86 ± 1.62* 3.22 ± 1.54 3.24 ± 1.53##
  1. Data expressed mean ± SD; LDL: low-density lipoprotein; HMW: high-molecular weight; *p < 0.05 difference compared with baseline, ##p < 0.01 compared absolute changes between the group A and group B following 24 weeks glimepiride treatment.